Market Overview

Marijuana Ruling: Is The DEA Re-Scheduling Bullish For Weed Stocks?

Share:
Marijuana Ruling: Is The DEA Re-Scheduling Bullish For Weed Stocks?
Related GWPH
Benzinga's Top Upgrades, Downgrades For December 12, 2018
The 2018 Farm Bill Vote: What You Need To Know
B. Riley FBR likes NASH players Viking Therapeutics and Galmed Pharma in premarket analyst action (Seeking Alpha)

Back in April, the U.S. Drug Enforcement Administration announced it would be reviewing the possibility of changing the federal classification of marijuana from Schedule 1 to Schedule 2.

Marijuana is currently listed among the DEA’s Schedule 1 drugs, which it describes as “most dangerous” and having “a high potential for abuse.” Other Schedule 1 drugs include heroin and LSD.

Schedule 2 drugs include legal prescription drugs like Ritalin and Adderal.

A re-scheduling of marijuana would clear the regulatory path for medical marijuana research and could be another step toward federal marijuana legalization.

Last week, the Santa Monica Observer reported the DEA will be making marijuana a Schedule 2 drug on August 1. The report cited an anonymous DEA lawyer with knowledge on the matter.

However, this week aNewDomain interviewed DEA staff coordinator Russ Baer, who didn't confirm the Santa Monica Observer report.

“We want to remove the roadblocks for research,” Baer said. He noted that GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is “showing some great preliminary results with CBD.”

Cannabidiol (CBD) is one of 113 active cannabinoids found in marijuana.

Related Link: 6 Weed Stocks That Aren't Penny Stocks

Despite the commitment to research, Baer added that the DEA is “not holding ourselves to any artificial timeline.”

He also noted marijuana isn't a top priority for the agency, which is primarily focused on the nation’s growing opioid crisis.

“The potential DEA ruling likely doesn't do much beyond encouraging more research into cannabis risks and benefits and make it perhaps easier for universities to get involved and for commercial entities to raise capital," industry expert Alan Brochstein told Benzinga. “I don't expect the DEA to reschedule cannabis but think it might do something with respect to CBD.”

So far in 2016, marijuana stocks have been as volatile as ever. GW Pharmaceuticals is up 27.3 percent. While some marijuana stocks have surged, such as AeroGrow International, Inc. (OTC: AERO) (+125.0 percent), others, like Zoned Properties Inc (OTC: ZDPY) (-63.4 percent) have plummeted.

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for GWPH

DateFirmActionFromTo
Dec 2018OppenheimerInitiates Coverage OnPerform
Dec 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Legal Exclusives Analyst Ratings General Best of Benzinga

 

Related Articles (AERO + GWPH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mobileye Rallies After 2 Quiet Sessions

Analysts Confident In Acceleron Pharma's Drug Trial Outcomes